Steven Cohen Bei Gene, Ltd. Transaction History
Point72 Asset Management, L.P.
- $42.2 Billion
- Q4 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 25,166 shares of BGNE stock, worth $5.71 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
25,166
Previous 667,166
96.23%
Holding current value
$5.71 Million
Previous $150 Million
96.9%
% of portfolio
0.01%
Previous 0.41%
Shares
3 transactions
Others Institutions Holding BGNE
# of Institutions
254Shares Held
45.1MCall Options Held
131KPut Options Held
95.6K-
Baker Bros. Advisors LP New York, NY9.53MShares$2.16 Billion19.52% of portfolio
-
Capital International Investors Los Angeles, CA6.11MShares$1.39 Billion0.22% of portfolio
-
Primecap Management CO Pasadena, CA5.1MShares$1.16 Billion0.74% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E93.8MShares$862 Million26.88% of portfolio
-
Baillie Gifford & CO3.67MShares$832 Million0.54% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...